References
- Boysen M, Schlicksupp L, Dreher I, Loebbert R, Richter M. SEC based method for size determination of immune complexes of therapeutic antibodies in animal matrix. J Immunol Res. 2016;2016:9096059. doi:https://doi.org/10.1155/2016/9096059.
- Jiskoot W, Kijanka G, Randolph TW, Carpenter JF, Koulov AV, Mahler H-C, Joubert MK, Jawa V, Narhi LO. Mouse models for assessing protein immunogenicity: lessons and challenges. J Pharm Sci. 2016;105(5):1567–9. doi:https://doi.org/10.1016/j.xphs.2016.02.031.
- van Schie KA, Wolbink GJ, Rispens T. Cross-reactive and pre-existing antibodies to therapeutic antibodies–Effects on treatment and immunogenicity. mAbs. 2015;7(4):662–71. doi:https://doi.org/10.1080/19420862.2015.1048411.
- Chatenoud L, Baudrihaye MF, Chkoff N, Kreis H, Goldstein G, Bach JF. Restriction of the human in vivo immune response against the mouse monoclonal antibody OKT3. J Immunol. 1986;137:830–38.
- van Schouwenburg PA, Kruithof S, Votsmeier C, van Schie K, Hart MH, de Jong RN, van Buren EEL, van Ham M, Aarden L, Wolbink G, et al. Functional analysis of the anti-adalimumab response using patient-derived monoclonal antibodies. J Biol Chem. 2014;289(50):34482–88. doi:https://doi.org/10.1074/jbc.M114.615500.
- van Schie KA, Hart MH, de Groot ER, Kruithof S, Aarden LA, Wolbink GJ, Rispens T. The antibody response against human and chimeric anti-TNF therapeutic antibodies primarily targets the TNF binding region. Ann Rheum Dis. 2015;74(1):311–14. doi:https://doi.org/10.1136/annrheumdis-2014-206237.
- van Schie KA, Kruithof S, van Schouwenburg PA, Vennegoor A, Killestein J, Wolbink G, Rispens T. Neutralizing capacity of monoclonal and polyclonal anti-natalizumab antibodies: the immune response to antibody therapeutics preferentially targets the antigen-binding site. J Allergy Clin Immunol. 2017;139(3):1035–7 e6. doi:https://doi.org/10.1016/j.jaci.2016.09.014.
- van Schie KA, Kruithof S, Ooijevaar-de Heer P, Derksen NIL, van de Bovenkamp FS, Saris A, Vidarsson G, Bentlage AEH, Jiskoot W, Romeijn S, et al. Restricted immune activation and internalisation of anti-idiotype complexes between drug and antidrug antibodies. Ann Rheum Dis. 2018;77(10):1471–79. doi:https://doi.org/10.1136/annrheumdis-2018-213299.
- Bian S, Stappen TV, Baert F, Compernolle G, Brouwers E, Tops S, Vries AD, Rispens T, Lammertyn J, Vermeire S, et al. Generation and characterization of a unique panel of anti-adalimumab specific antibodies and their application in therapeutic drug monitoring assays. J Pharm Biomed Anal. 2016;125:62–67. doi:https://doi.org/10.1016/j.jpba.2016.03.029.
- Tada M, Suzuki T, Ishii-Watabe A. Development and characterization of an anti-rituximab monoclonal antibody panel. mAbs. 2018;10(3):370–79. doi:https://doi.org/10.1080/19420862.2018.1424610.
- Weber J, Peng H, Rader C. From rabbit antibody repertoires to rabbit monoclonal antibodies. Exp Mol Med. 2017;49:e305.
- Seeber S, Ros F, Thorey I, Tiefenthaler G, Kaluza K, Lifke V, Fischer JAA, Klostermann S, Endl J, Kopetzki E, et al. A robust high throughput platform to generate functional recombinant monoclonal antibodies using rabbit B cells from peripheral blood. PLoS One. 2014;9(2):e86184. doi:https://doi.org/10.1371/journal.pone.0086184.
- Dohmen SE, Mulder A, Verhagen OJ, Eijsink C, Franke-van Dijk ME, van der Schoot CE. Production of recombinant Ig molecules from antigen-selected single B cells and restricted usage of Ig-gene segments by anti-D antibodies. J Immunol Methods. 2005;298(1–2):9–20. doi:https://doi.org/10.1016/j.jim.2004.12.013.
- Labrijn AF, Buijsse AO, van den Bremer ET, Verwilligen AY, Bleeker WK, Thorpe SJ, Killestein J, Polman CH, Aalberse RC, Schuurman J, et al. Therapeutic IgG4 antibodies engage in Fab-arm exchange with endogenous human IgG4 in vivo. Nat Biotechnol. 2009;27(8):767–71. doi:https://doi.org/10.1038/nbt.1553.
- Rispens T, Davies AM, Ooijevaar-de Heer P, Absalah S, Bende O, Sutton BJ, Vidarsson G, Aalberse RC. Dynamics of inter-heavy chain interactions in human immunoglobulin G (IgG) subclasses studied by kinetic Fab arm exchange. J Biol Chem. 2014;289(9):6098–109. doi:https://doi.org/10.1074/jbc.M113.541813.
- Peng HP, Lee KH, Jian JW, Yang AS. Origins of specificity and affinity in antibody-protein interactions. Proc Natl Acad Sci U S A. 2014;111(26):E2656–65. doi:https://doi.org/10.1073/pnas.1401131111.
- Kringelum JV, Lundegaard C, Lund O, Nielsen M. Reliable B cell epitope predictions: impacts of method development and improved benchmarking. PLoS Comput Biol. 2012;8(12):e1002829. doi:https://doi.org/10.1371/journal.pcbi.1002829.
- Jespersen MC, Mahajan S, Peters B, Nielsen M, Marcatili P. Antibody specific B-cell epitope predictions: leveraging information from antibody-antigen protein complexes. Front Immunol. 2019;10:298. doi:https://doi.org/10.3389/fimmu.2019.00298.
- Chiesa MD, Martensen PM, Simmons C, Porakishvili N, Justesen J, Dougan G, Roitt IM, Delves PJ, Lund T. Refocusing of B-cell responses following a single amino acid substitution in an antigen. Immunology. 2001;103(2):172–78. doi:https://doi.org/10.1046/j.1365-2567.2001.01242.x.
- Ma B, Elkayam T, Wolfson H, Nussinov R. Protein-protein interactions: structurally conserved residues distinguish between binding sites and exposed protein surfaces. Proc Natl Acad Sci U S A. 2003;100(10):5772–77. doi:https://doi.org/10.1073/pnas.1030237100.
- Rispens T, Leeuwen A, Vennegoor A, Killestein J, Aalberse RC, Wolbink GJ, Aarden LA. Measurement of serum levels of natalizumab, an immunoglobulin G4 therapeutic monoclonal antibody. Anal Biochem. 2011;411(2):271–76. doi:https://doi.org/10.1016/j.ab.2011.01.001.
- Rispens T, de Vrieze H, de Groot E, Wouters D, Stapel S, Wolbink GJ, Aarden LA. Antibodies to constant domains of therapeutic monoclonal antibodies: anti-hinge antibodies in immunogenicity testing. J Immunol Methods. 2012;375(1–2):93–99. doi:https://doi.org/10.1016/j.jim.2011.09.011.
- Ehrenmann F, Kaas Q, Lefranc MP. IMGT/3Dstructure-DB and IMGT/DomainGapAlign: a database and a tool for immunoglobulins or antibodies, T cell receptors, MHC, IgSF and MhcSF. Nucleic Acids Res. 2010;38(Databaseissue):D301–7. doi:https://doi.org/10.1093/nar/gkp946.
- Lighaam LC, Vermeulen E, Bleker T, Meijlink KJ, Aalberse RC, Barnes E, Culver EL, van Ham SM, Rispens T. Phenotypic differences between IgG4+ and IgG1+ B cells point to distinct regulation of the IgG4 response. J Allergy Clin Immunol. 2014;133(1):267–70e1–6. doi:https://doi.org/10.1016/j.jaci.2013.07.044.
- Vink T, Oudshoorn-Dickmann M, Roza M, Reitsma JJ, de Jong RN. A simple, robust and highly efficient transient expression system for producing antibodies. Methods. 2014;65(1):5–10. doi:https://doi.org/10.1016/j.ymeth.2013.07.018.